ArticleScience progress
Blood glucose control, magnesium status, and diabetic retinopathy in patients with type 2 diabetes mellitus: Evidence from NHANES 2005-2018.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveThis study sought to explore the association of magnesium (Mg) status and blood glucose control, represented by Mg depletion score (MDS) and hemoglobin A1c (HbA1c) level, respectively, with the risk of diabetic retinopathy (DR) among type 2 diabetes mellitus (T2DM) patients, and whether there were interactions between Mg status and blood glucose control on the risk of DR.MethodsData of this cross-sectional study were extracted from the National Health and Nutrition Examination Surveys (NHANES) database 2005-2018. MDS was an indicator to assess the overall Mg status in the human body that considers the pathophysiological factors influencing the kidneys' reabsorption capability. Blood glucose control was represented by hemoglobin A1c (HbA1c) and HbA1c level ≥7% referred to poor blood glucose control. Receiver Operating curve (ROC) analysis was performed to evaluate the predictive performance of MDS and HbA1c for DR. Weighted univariate and multivariate analyses were utilized to explore the MDS and HbA1c and their interactions effects on the risk of DR, with odds ratios (ORs), 95% confidence intervals (CIs), relative excess risk due to interactions (RERI) and attributable proportion due to interactions (AP). These interactions were further explored based on the age, gender, and cardiovascular disease (CVD) history.ResultsA total of 4487 T2DM patients were included, of whom 942 (20.99%) had DR. After covariate adjustment, both high MDS (≥2) and elevated HbA1c levels (≥7%) demonstrated significant independent associations with increased DR risk. ROC analysis showed MDS (AUC = 0.766) and HbA1c (AUC = 0.749) in fully adjusted models. Significant interactions between MDS and HbA1c amplified DR risk beyond individual effects, with this pattern most pronounced among female patients, those aged ≥60 years, and individuals with a cardiovascular disease history.ConclusionsThe results of this study suggested that high MDS as well as high HbA1c level may have interaction effects on the high risk of DR among T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.